United States was 10x Genomics’s largest region in fiscal 2025, bringing in $346.51M of $642.82M (54%).
| Geography | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|
| United States | $284.99M | $360.09M | $334.32M | $346.51M | |||||
| Europe, Middle East & Africa | $117.07M | $142.28M | $159.76M | $161.72M | |||||
| North America | — | — | — | — | |||||
| Asia-Pacific (Excluding China) | $41.21M | $52.29M | $45.96M | $52.07M | |||||
| China | $64.36M | $50.97M | $57.30M | $70.26M | |||||
| Asia-Pacific | — | — | — | — | |||||
| Asia Pacific | — | — | — | — | |||||
| Americas (Excluding United States) | $8.79M | $13.10M | $13.45M | $12.26M | |||||
| North America (Excluding United States) | — | — | — | — | |||||
| Total | $516.41M | $618.73M | $610.79M | $642.82M |
10x Genomics brought in $642.82M from its five regions in fiscal 2025, the year ended December 31, 2025. That was up 5.2% from $610.79M in fiscal 2024. United States was the largest at $346.51M (53.9%), ahead of Europe, Middle East & Africa at $161.72M (25.2%) and China at $70.26M (10.9%). The other two regions brought in $64.33M combined.
Compared with fiscal 2024, China grew fastest, up 22.6% to $70.26M. Every region above 2% of revenue grew. From fiscal 2022 to 2025, combined revenue from these regions grew from $516.41M to $642.82M, a compound annual growth rate of 7.6%. United States' share of the total fell from 55.2% to 53.9%.
License & Royalty Revenue was 10x Genomics’s largest product and service line in fiscal 2025, bringing in $46.14M of $135.64M (34%).
| Product and Service | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Chromium | $58.55M | — | — | — | |||||
| Single Cell | — | $47.87M | $35.21M | $22.67M | |||||
| Consumables | — | — | — | — | |||||
| Spatial | $13.84M | $75.61M | $57.50M | $34.11M | |||||
| Instruments | — | — | — | — | |||||
| Instuments | — | — | — | — | |||||
| License & Royalty Revenue | — | — | $321.00K | $46.14M | |||||
| Services | $8.43M | $15.70M | $24.32M | $32.73M | |||||
| Service | — | — | — | — | |||||
| Total | $80.82M | $139.17M | $117.35M | $135.64M |
10x Genomics brought in $135.64M from its four product and service lines in fiscal 2025, the year ended December 31, 2025. That is less than the $642.82M it reports by geography, so these lines do not cover all of its revenue. License & Royalty Revenue was the largest at $46.14M (34.0%), ahead of Spatial at $34.11M (25.1%) and Services at $32.73M (24.1%). The remaining line, Single Cell, brought in $22.67M.
Compared with fiscal 2024, License & Royalty Revenue grew fastest, up 14,272.3% to $46.14M, while Spatial fell the most, down 40.7% to $34.11M.
10x Genomics began breaking out Single Cell in fiscal 2023 and License & Royalty Revenue in fiscal 2024. 10x Genomics stopped reporting Chromium as a separate line after fiscal 2022, when it brought in $58.55M.
10x Genomics (TXG) reports its revenue by geography and by product and service. In fiscal 2025, United States was its largest region, bringing in $346.51M (53.9% of the total), followed by Europe, Middle East & Africa at $161.72M (25.2%).
United States was 10x Genomics' largest region in fiscal 2025, bringing in $346.51M, or 53.9% of the $642.82M total across its five regions.
License & Royalty Revenue was 10x Genomics' largest product and service line in fiscal 2025, bringing in $46.14M, or 34.0% of the $135.64M total across its four product and service lines.
Among 10x Genomics' regions that make up at least 2% of revenue, China grew fastest in fiscal 2025, up 22.6% from $57.30M to $70.26M.
Every figure comes from 10x Genomics' annual financial filings, as reported. Each line keeps the name 10x Genomics gives it, and years follow its fiscal calendar.
10x Genomics' revenue by geography goes back to fiscal 2017, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.